Danielle M. Lauzon

Ms. Lauzon’s representation of start-up and later stage companies spans the entire corporate life cycle, including formation matters, general corporate representation and counseling, venture capital financings, public offerings and mergers and acquisitions. Her clients are in the life sciences, software and information technology services industries. Her recent representations include:

• Onyx Pharmaceuticals in its $10.4 billion sale to Amgen, one of the largest biotech transactions ever
• AMRI in its $358 million acquisition of Euticals and $174 million acquisition of Gadea Pharmaceutical Group
• Aerpio Therapeutics in its $40 million reverse merger and private placement
• Alector LLC in its Series A, Series B, Series C, and Series D financings
• Promedior, Inc. in its strategic agreement with Bristol-Myers Squibb
• Unum Therapeutics in its $65 million Series B financing
• ProQR Therapeutics N.V. in its $97.5 million initial public offering
• Blueprint Medicines in its $230 million and  $125 million follow-on offerings, $25 million Series B,and $50 million Series C financing
• Conformis in its $50 million offering of stock with Canaccord Genuity
• AbilTo, Inc. in its Series A, Series B and Series C financings
• Zalicus Inc. in its sale to Epirus Biopharmaceuticals
• Moderna Therapeutics in the closing of a $110 million financing round
• Hasbro, Inc., a global branded play company and owner of some of the world’s most popular brands, on its acquisition of a 70% interest in Backflip Studios, a developer and publisher of mobile games of IOS and Android devices
• Picis Solutions in its sale to Ingenix, a subsidiary of UnitedHealth Group
• Phase Forward in its sale to Oracle Corporation